» Articles » PMID: 39375734

Female-bias in Systemic Lupus Erythematosus: How Much is the X Chromosome to Blame?

Overview
Journal Biol Sex Differ
Publisher Biomed Central
Specialties Biology
Physiology
Date 2024 Oct 7
PMID 39375734
Authors
Affiliations
Soon will be listed here.
Abstract

Systemic lupus erythematosus (SLE or lupus) is an immune-mediated disease associated with substantial medical burden. Notably, lupus exhibits a striking female bias, with women having significantly higher susceptibility compared to men, up to 14-fold higher in some ethnicities. Supernumerary X chromosome syndromes, like Klinefelter (XXY) and Triple X syndrome (XXX), also present higher SLE prevalence, whereas Turner syndrome (XO) displays lower prevalence. Taken together, SLE prevalence in different X chromosome dosage sceneries denotes a relationship between the number of X chromosomes and the risk of developing lupus. The dosage of X-linked genes, many of which play roles in the immune system, is compensated between males and females through the inactivation of one of the two X chromosomes in female cells. X-chromosome inactivation (XCI) initiates early in development with a random selection of which X chromosome to inactivate, a choice that is then epigenetically maintained in the daughter cells. This process is regulated by the X-Inactive-Specific Transcript (XIST), encoding for a long non-coding RNA, exclusively expressed from the inactive X chromosome (Xi). XIST interacts with various RNA binding proteins and chromatin modifiers to form a ribonucleoprotein (RNP) complex responsible for the transcriptional silencing and heterochromatinization of the Xi. This ensures stable silencing of most genes on the X chromosome, with only a few genes able to escape this process. Recent findings suggest that the molecular components involved in XCI, or their dysregulation, contribute to the pathogenesis of lupus. Indeed, nonrandom XCI, elevated gene escape from XCI, and the autoimmune potential of the XIST RNP complex have been suggested to contribute to auto-immune diseases, such as lupus. This review examines these current hypotheses concerning how this dosage compensation mechanism might impact the development of lupus, shedding light on potential mechanisms underlying the pathogenesis of the disease.

References
1.
Koshy M, Berger D, Crow M . Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest. 1996; 98(3):826-37. PMC: 507493. DOI: 10.1172/JCI118855. View

2.
Barber M, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow N . Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021; 17(9):515-532. PMC: 8982275. DOI: 10.1038/s41584-021-00668-1. View

3.
Ha N, Ding N, Hong R, Liu R, Roca X, Luo Y . The lupus autoantigen La/Ssb is an Xist-binding protein involved in Xist folding and cloud formation. Nucleic Acids Res. 2021; 49(20):11596-11613. PMC: 8599922. DOI: 10.1093/nar/gkab1003. View

4.
Yen E, Singh R . Brief Report: Lupus-An Unrecognized Leading Cause of Death in Young Females: A Population-Based Study Using Nationwide Death Certificates, 2000-2015. Arthritis Rheumatol. 2018; 70(8):1251-1255. PMC: 6105528. DOI: 10.1002/art.40512. View

5.
Sasidhar M, Itoh N, Gold S, Lawson G, Voskuhl R . The XX sex chromosome complement in mice is associated with increased spontaneous lupus compared with XY. Ann Rheum Dis. 2012; 71(8):1418-22. PMC: 4452281. DOI: 10.1136/annrheumdis-2011-201246. View